摘要
目的研究琥珀酸美托洛尔缓释片联合麝香保心丸治疗冠心病心绞痛的临床疗效。方法80例冠心病心绞痛患者,利用随机数字表法分为对照组和观察组,各40例。对照组给予琥珀酸美托洛尔缓释片治疗,观察组在对照组基础上加用麝香保心丸治疗。比较两组的心肌酶谱[肌酸激酶(CK)、肌钙蛋白T(cTnT)、肌酸激酶同工酶(CK-MB)]水平、心功能指标[左室射血分数(LVEF)、左心室质量指数(LVMI)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)]、心绞痛发作情况、临床疗效、不良反应发生情况。结果治疗后,两组CK、cTnT、CK-MB水平均低于本组入组时,且观察组CK(67.52±10.18)U/L、cTnT(139.54±4.09)ng/L、CK-MB(55.06±4.54)U/L低于对照组的(92.17±12.43)U/L、(151.63±5.73)ng/L、(76.80±6.65)U/L(P<0.05)。治疗后,两组LVEF高于本组入组时,LVMI低于本组入组时,LVEDD、LVESD小于本组入组时,且观察组LVEF(54.93±6.74)%高于对照组的(50.16±5.36)%,LVMI(111.30±4.28)g/m^(2)低于对照组的(119.90±6.81)g/m^(2),LVEDD(40.11±2.13)mm、LVESD(41.50±2.40)mm小于对照组的(45.70±3.62)、(47.24±4.16)mm(P<0.05)。治疗后,两组心绞痛发作次数少于入组时,心绞痛持续时间短于入组时,且观察组心绞痛发作次数(2.01±0.37)次/周少于对照组的(4.05±0.58)次/周,心绞痛持续时间(2.06±0.33)min/次短于对照组的(4.23±0.45)min/次(P<0.05)。观察组治疗总有效率97.50%明显高于对照组的82.50%(P<0.05)。两组不良反应发生率比较差异不大(P>0.05)。结论冠心病心绞痛患者采用琥珀酸美托洛尔缓释片联合麝香保心丸治疗安全有效,可减轻心肌损伤坏死,有效改善心功能与心绞痛症状,临床推广应用价值高。
Objective To study the clinical efficacy of metoprolol succinate sustained-release tablets combined with Shexiang Baoxin pill on angina pectoris of coronary heart disease.Methods A total of 80 patients with angina pectoris of coronary heart disease were divided into control group and observation group according to random numerical table,with 40 cases in each group.The control group was treated with metoprolol succinate sustained-release tablets,while the observation group was treated with Shexiang Baoxin pill.Comparison of myocardial enzymogram[creatine kinase(CK),cardiac troponin T(cTnT),creatine kinase isoenzyme(CK-MB)],cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular mass index(LVMI),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)]and angina pectoris attack,clinical efficacy,and occurrence of adverse reactions between the two groups.Results After treatment,the levels of CK,cTnT and CK-MB in both groups were lower than those at the time of enrollment in this group;the observation group had CK of(67.52±10.18)U/L,cTnT of(139.54±4.09)ng/L and CK-MB of(55.06±4.54)U/L,which were lower than(92.17±12.43)U/L,(151.63±5.73)ng/L and(76.80±6.65)U/L in the control group(P<0.05).After treatment,LVEF in both groups was higher than that at the time of enrollment in this group,LVMI was lower than that at the time of enrollment in this group,and LVEDD and LVESD were smaller than those at the time of enrollment in this group;the observation group had a higher LVEF of(54.93±6.74)%than(50.16±5.36)%in the control group;the observation group had a lower LVMI of(111.30±4.28)g/m^(2)than(119.90±6.81)g/m^(2)in the control group;the observation group had LVEDD of(40.11±2.13)mm and LVESD of(41.50±2.40)mm,which were smaller than(45.70±3.62)and(47.24±4.16)mm in the control group(P<0.05).After treatment,the frequency of angina pectoris in both group was less than that at the time of enrollment in this group,and the duration of angina pectoris was shorter than that at the time of enrollment in this group;the frequency of angina pectoris in the observation group was(2.01±0.37)times/week,which was less than(4.05±0.58)times/week in the control group;the duration of angina pectoris in the control group was(2.06±0.33)min/time,which was shorter than(4.23±0.45)min/time in the control group(P<0.05).The total effective rate of 97.50%in the observation group was significantly higher than 82.50%in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of metoprolol succinate sustained-release tablets and Shexiang Baoxin pills is effective and safe in the treatment of patients with angina pectoris of coronary heart disease,and can effectively improve cardiac function and angina pectoris symptoms,and has high clinical application value.
作者
朱艾华
ZHU Ai-hua(Jinxiang County People's Hospital,Jining 272200,China)
出处
《中国实用医药》
2025年第10期1-5,共5页
China Practical Medicine
关键词
冠心病心绞痛
琥珀酸美托洛尔缓释片
麝香保心丸
疗效
Angina pectoris of coronary heart disease
Metoprolol succinate sustained-release tablets
Shexiang Baoxin pill
Efficacy
